All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
MPN Hub spotlight: Momelotinib mechanism of action
Bookmark this article
⭐MPN Hub spotlight: Momelotinib mechanism of action ⭐
Momelotinib is approved for the treatment of patients with anemic myelofibrosis (MF), regardless of prior MF therapy.
A differentiated mechanism of action inhibiting Janus kinase (JAK)1, JAK2, and activin A receptor, type I (ACVR1) underlies reductions in constitutional symptoms, splenomegaly, and MF-related anemia.
This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
- Tefferi A, Pardanani A. Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval. Blood Cancer J. 2024;14:47. DOI:1038/s41408-024-01029-3
- Tefferi A, Pardanani A, Gangat N. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. Haematologica. 2023;108(11):2919-2932. DOI:3324/haematol.2022.282612
- Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022;15:7. DOI:1186/s13045-021-01157-4
- Verstovsek S, Mesa R, Gupta V, et al. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv. 2023;7(14):3582-3591. DOI:1182/bloodadvances.2022009311
- Liu T, et al. Association between hemoglobin improvement and patient-reported outcomes in patients with myelofibrosis and anemia: post hoc pooled analysis of momelotinib phase 3 trials. Poster #MPN-085. SOHO 2024 Annual Meeting; Sep 4-7, 2024; Houston, US
Your opinion matters
26 votes - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox